ANAPTYSBIO, INC ANAB
We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which we completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis ("RA"), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease ("CeD") and eosinophilic esophagitis ("EoE"), and ANB101, a BDCA2 modulator, in a Phase 1a trial. We also discovered and out-licensed, in financial collaborations, multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly) or "Jemperli") to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals Inc. ("Vanda"). We currently recognize revenue from milestones and royalties achieved under our immuno-oncology collaboration with GSK and license and transition services revenue from our collaboration with Vanda.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $234.6M | $91.3M | $17.2M | $10.3M | $63.2M | $75.0M | $8.0M | $5.0M | $10.0M | $16.7M |
| R&D | — | — | — | $88.8M | $98.5M | $80.0M | $99.3M | $56.2M | $29.4M | $15.4M |
| SG&A | $50.7M | $42.4M | $41.9M | $36.6M | $21.5M | $18.9M | $16.1M | $15.5M | $9.3M | $4.3M |
| Total operating expenses | $186.7M | $206.2M | $181.6M | $125.4M | $120.0M | $98.9M | $115.4M | $71.7M | $38.8M | $19.7M |
| Operating income | $47.9M | -$114.9M | -$164.4M | -$115.2M | -$56.8M | -$23.9M | -$107.4M | -$66.7M | -$28.8M | -$3.0M |
| Interest expense | — | — | — | — | $0 | $0 | $1.0M | $1.7M | $1.8M | $458.0K |
| Pre-tax income | -$13.1M | -$145.2M | -$163.6M | -$128.7M | -$57.8M | -$19.9M | -$97.5M | -$61.8M | -$30.1M | -$4.3M |
| Income tax | $164.0K | $3.0K | $4.0K | $24.0K | $0 | $0 | $152.0K | $192.0K | $0 | $0 |
| Net income | -$13.2M | -$145.2M | -$163.6M | -$128.7M | -$57.8M | -$19.9M | -$97.3M | -$61.7M | -$30.1M | -$4.3M |
| EPS, basic | -0.46 | -5.12 | -6.08 | -4.57 | -2.11 | -0.73 | -3.60 | -2.50 | -1.52 | -1.62 |
| EPS, diluted | -0.46 | -5.12 | -6.08 | -4.57 | -2.11 | -0.73 | -3.60 | -2.50 | -1.52 | -1.62 |
| Shares, diluted (wtd. avg.) | 28.8M | 28.4M | 26.9M | 28.2M | 27.4M | 27.3M | 27.1M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $238.2M | $123.1M | $36.0M | $71.3M | $495.7M | $250.5M | $171.1M | $113.7M | $81.2M | $51.3M |
| Short-term investments | $73.4M | $262.3M | $354.9M | $369.9M | $52.4M | $143.2M | $203.2M | $313.5M | $167.2M | $0 |
| Receivables | $33.9M | $40.8M | $6.9M | $1.4M | $876.0K | $0 | — | — | $0 | $1.2M |
| Total current assets | $350.2M | $431.9M | $406.8M | $447.2M | $553.9M | $396.6M | $377.7M | $434.2M | $252.7M | $58.2M |
| Property, plant and equipment | $1.4M | $1.8M | $2.1M | $2.1M | $2.3M | $1.8M | $1.6M | $1.4M | $665.0K | $471.0K |
| Total assets | $364.4M | $483.8M | $452.4M | $610.4M | $643.1M | $416.6M | $435.2M | $509.0M | $329.4M | $62.2M |
| Accounts payable | $3.9M | $4.0M | $4.7M | $2.8M | $1.7M | $4.2M | $16.2M | $5.4M | $2.3M | $2.3M |
| Total current liabilities | $38.6M | $45.4M | $37.4M | $26.1M | $16.1M | $19.8M | $29.5M | $21.8M | $14.1M | $5.7M |
| Retained earnings | -$772.6M | -$759.3M | -$614.1M | -$450.5M | -$321.8M | -$264.0M | -$244.0M | -$146.7M | -$85.0M | -$54.9M |
| Total equity | $37.2M | $70.9M | $88.1M | $262.1M | $356.4M | $396.7M | $405.0M | $486.4M | $307.6M | -$38.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $19.7M | -$135.3M | -$120.8M | -$73.6M | -$45.9M | -$14.2M | -$69.5M | -$48.5M | -$19.4M | -$9.0M |
| Depreciation and amortisation | $559.0K | $606.0K | $652.0K | $675.0K | $619.0K | $559.0K | $514.0K | $315.0K | $183.0K | $233.0K |
| Stock-based compensation | $36.1M | $34.0M | $33.2M | $27.4M | $15.3M | — | — | — | $4.4M | $1.2M |
| Capital expenditure | $87.0K | $358.0K | $807.0K | $358.0K | $1.4M | $569.0K | $805.0K | $1.1M | $290.0K | $50.0K |
| Investing cash flow | $228.0M | $95.4M | $144.8M | -$394.8M | $38.8M | $94.5M | $131.4M | -$142.5M | -$243.1M | -$50.0K |
| Financing cash flow | -$132.6M | $127.1M | -$59.3M | $44.0M | $252.3M | -$879.0K | -$4.5M | $223.4M | $292.5M | $8.6M |
| Buybacks | $68.6M | $456.0K | $50.0M | $0 | $0 | — | — | $0 | $0 | $1.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-288408.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.7M | $10.0M | $5.0M | $8.0M | $75.0M | $63.2M | $10.3M | $17.2M | $91.3M | $234.6M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$4.3M | -$30.1M | -$61.7M | -$97.3M | -$19.9M | -$57.8M | -$128.7M | -$163.6M | -$145.2M | -$13.2M |
Recent filings and events
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Material agreement signed Item 1.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Officer or director change Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |